Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Net Cash Flow (2016 - 2025)

ImmunityBio (IBRX) has disclosed Net Cash Flow for 12 consecutive years, with $28.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 11.16% to $28.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$54.5 million through Dec 2025, up 55.28% year-over-year, with the annual reading at -$54.5 million for FY2025, 55.28% up from the prior year.
  • Net Cash Flow for Q4 2025 was $28.1 million at ImmunityBio, up from -$76.7 million in the prior quarter.
  • The five-year high for Net Cash Flow was $134.5 million in Q3 2023, with the low at -$144.5 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $2.7 million, with a median of $5.1 million recorded in 2021.
  • The sharpest move saw Net Cash Flow tumbled 1564.0% in 2022, then soared 27334.8% in 2023.
  • Over 5 years, Net Cash Flow stood at $116.5 million in 2021, then crashed by 99.73% to $319000.0 in 2022, then skyrocketed by 27334.8% to $87.5 million in 2023, then crashed by 63.87% to $31.6 million in 2024, then fell by 11.16% to $28.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $28.1 million, -$76.7 million, and $76.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.